给战友点希望－－硝唑尼特治疗慢肝

别愁

Replico 网站上的NEWs上说有6例试验情况将在北京亚太肝病会议上提交，但文献（大会摘要报道）上未提及人数。
At the time of abstract submission,one patient has already exhibited clear signs of a sustained virologic response(HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) for 8 continuousweeks off treatment after receiving only 23 weeks of treatment with REP9AC.
我想，提出这个具体例子，是想重点说明在治疗了23周后中断治疗的8周内（截止到摘要提交日）一直有“持续应答”。其他几例可能试验一直在进行，只简单说明“表面抗原消失，保护性免疫产生”。几个人的试验设计可能不同，报道的侧重点也有不同。不管怎样，这样的结果如果在III期的试验中能复制的话，我们就有救了。



[ 本帖最后由 别愁 于 2010-4-5 20:11 编辑 ]

fromdesert34

原帖由 别愁 于 2010-4-5 20:01 发表
Replico 网站上的NEWs上说有6例试验情况将在北京亚太肝病会议上提交，但文献（大会摘要报道）上未提及人数。
At the time of abstract submission,one patient has already exhibited clear signs of a sustained virologi ...

不管怎样rep9ac就算出来估计也要很多年。。。现在还是硝是最好的选择。。

Interferon

稀里糊涂的翻译了一下，很多地方不理解
，凑合着看看吧。






Background: REP9AC is a DNA-based amphipathic polymer whose antiviral activity is linked to targeting viral glycoproteins important for viral entry and/or release.
背景： REP9AC是一种以脱氧核糖核酸为基础的两性分子高聚物，它的抗病毒活性作用于病毒糖蛋白进入和/或释放的关键环节。

The preclinical evaluation of 28 days of REP 9AC therapy in ducks persistently infected with DHBV demonstrated rapid clearance of DHBV DNA, DHBsAg and rapid appearance of anti-DHBs antibodies in 55% of ducks whose blood had no detectable evidence of DHBV infection 16 weeks after cessation of REP 9AC therapy.
临床前期试验的评估中，在给持续感染鸭乙肝病毒以REP9AC二十八天的治疗显示出了鸭乙肝病毒DNA、鸭血清表面抗原的快速清除，并且在终止REP9AC的治疗十六周后，百分之五十五的鸭已经产生了鸭乙肝抗体，这些鸭的血液中已经无法检测到鸭乙肝病毒感染的证据。
The ability of REP 9AC to treat human patients with CHB is currently being evaluated in a proof of concept trial.
REP9AC用于治疗人类慢性乙型肝炎患者的能力目前正在试验阶段的证明中被评估。
Methods: Patients with CHB were subjected to REP9AC therapy administered by slow continuous infusion.
方法：慢性乙型肝炎患者在REP9AC的治疗中接受缓慢持续滴注。
Safety and virologic response (HBV DNA, HBsAg, anti-HBs) were assessed weekly, either at the trial site or by confirmatory testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples at a separate location using the Architect TM testing platform.
不论在试验地点还是在一个分开的地点应用Architect（注册商标）测试平台对冷冻血清样本进行确认性的试验（表面抗原、e抗原、表面抗体、e抗体），每周的评估结果都是安全而且病毒学应答（HBV DNA、表面抗原、表面抗体）。
Results: Interim data has shown that all patients treated to date have cleared HBsAg and developed protective immunity.
结果：中期数据显示迄今为止所有接受治疗的患者都已清除了表面抗原且形成了保护性免疫力。
Clearance of HBsAg and development of protective levels of anti-HBs occurred as early as 7 days following initiation of treatment at higher doses.
在更高剂量的治疗下，表面抗原的清除和保护级别的表面抗体形成早在开始治疗的七天之后出现。
At the time of abstract submission, one patient has already exhibited clear signs of a sustained virologic response (HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) for 8 continuous weeks off treatment after receiving only 23 weeks of treatment with REP9AC.
摘要提交的时候，一名患者已经显示出了明确的迹象表明产生了持续八周停止治疗后的持久应答（HBV DNA阴性、表面抗原阴性、e抗原阴性、表面抗体阳性、e抗体阳性），这名患者仅仅接受了23周REP9AC的治疗。
Conclusions: These results demonstrate that amphipathic polymers are effective in rapidly reducing HBsAg levels in CHB patients which allows patients to seroconvert.
结论：这些结果说明了这种两性分子高聚物在允许患者血清学转换的慢性乙型肝炎患者中快速降低表面抗原水平的有效性。
The rapid appearance of anti-HBs and anti-HBe antibodies in these patients, the best predictors of SVR in patients with CHB, suggest that amphipathic polymers could become an important new tool in the treatment of CHB.
在这些患者中快速出现的表面抗体和e抗体，以及慢性肝炎患者持久应答的良好预测，显示出这种两性分子高聚物会成为在慢性乙型肝炎治疗中一个新的重要工具

别愁

很好的啦，辛苦了，多谢了

富贵数字

原帖由 Interferon 于 2010-4-5 20:44 发表
稀里糊涂的翻译了一下，很多地方不理解
，凑合着看看吧。






Background: REP9AC is a DNA-based amphipathic polymer whose antiviral activity is linked to targeting viral glycoproteins important for viral en ...

谢谢了

fromdesert34

结果：中期数据显示迄今为止所有接受治疗的患者都已清除了表面抗原且形成了保护性免疫力。
还是没搞懂究竟其他接受治疗的患者和那例持续性应答的患者有何区别。

怕脂肪肝

太专业了，但是还要顶

Interferon

不用理解了，反正这种药猴年马月也不能面世。离我们远着呢。
重点还是关注硝唑尼特吧。

怕脂肪肝

硝唑尼特也不懂但是还要顶

Interferon

原帖由 怕脂肪肝 于 2010-4-5 21:13 发表
硝唑尼特也不懂但是还要顶

把这个贴子从头至尾看一遍，怎么也能懂一些吧。